Mid-stage cholesterol data sends Isis stock soaring

Isis' experience at the AHA meeting was decidedly happier than Pfizer's, with the drug developer seeing its stock surge 28 percent on the review of its Phase II data for ISIS 301012, an experimental drug for lowering the level of "bad" cholesterol. Patients taking 300mg a week for five weeks had an average reduction of 51 percent in bad LDL cholesterol, a 42 percent drop in total cholesterol and a 41 percent decline in triglycerides. All outcomes were ahead of what patients recorded on statins alone. Increasing the dosage for patients with high cholesterol for three months also spurred impressive results.

- here's a report from MarketWatch for more

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.